Download PDF

1. Company Snapshot

1.a. Company Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology.


The company was incorporated in 2015 and is based in South San Francisco, California.

Show Full description

1.b. Last Insights on KZR

Kezar Life Sciences' recent performance has been driven by several positive developments. The company has made progress with its zetomipzomib program in autoimmune hepatitis, securing a Type C meeting with the FDA. Additionally, Enodia Therapeutics has acquired Kezar's Sec61-based discovery and development program assets. Aurinia Pharmaceuticals has also announced plans to acquire Kezar Life Sciences for $6.955 in cash per share plus a contingent value right. This acquisition may provide a positive outcome for shareholders. According to Marketbeat.com, analysts have a consensus "Reduce" rating on the stock, with two sell and four hold recommendations.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS

Apr -14

Source: globenewswire.com

Card image cap

Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders

Apr -07

Source: globenewswire.com

Card image cap

Lifecore Biomedical (NASDAQ:LFCR) and Kezar Life Sciences (NASDAQ:KZR) Head-To-Head Review

Apr -02

Source: defenseworld.net

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)

Mar -30

Source: prnewswire.com

Card image cap

Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders

Mar -30

Source: prnewswire.com

Card image cap

KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders

Mar -30

Source: businesswire.com

Card image cap

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Mar -30

Source: businesswire.com

Card image cap

Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages

Mar -16

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.93%)

6. Segments

Immune-mediated Diseases and Cancer Therapeutics

Expected Growth: 10.93%

Kezar Life Sciences' Immune-mediated Diseases and Cancer Therapeutics segment growth is driven by increasing demand for novel therapies, advancements in immunology research, and a growing pipeline of promising candidates. The company's focus on modulating protein degradation pathways and targeting immune cells also contributes to its growth, as these approaches have shown potential in treating various immune-mediated diseases and cancers.

7. Detailed Products

Zerviatinib

Zerviatinib is an oral, selective inhibitor of the tyrosine kinase ZAK, which is a key regulator of the NLRP3 inflammasome. It is being developed as a potential treatment for severe and debilitating autoimmune diseases.

KZR-616

KZR-616 is a selective inhibitor of the immunoproteasome, which is a key regulator of immune cell activation. It is being developed as a potential treatment for severe autoimmune diseases.

8. Kezar Life Sciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Kezar Life Sciences, Inc. is moderate due to the presence of alternative treatments and therapies for cancer and autoimmune diseases.

Bargaining Power Of Customers

The bargaining power of customers for Kezar Life Sciences, Inc. is low due to the company's focus on rare and orphan diseases, which limits the negotiating power of patients and healthcare providers.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Kezar Life Sciences, Inc. is moderate due to the company's reliance on a limited number of suppliers for raw materials and services.

Threat Of New Entrants

The threat of new entrants for Kezar Life Sciences, Inc. is high due to the growing interest in biotechnology and pharmaceutical research, which attracts new companies and investors to the industry.

Intensity Of Rivalry

The intensity of rivalry for Kezar Life Sciences, Inc. is high due to the competitive landscape of the biotechnology and pharmaceutical industries, where companies compete for market share and intellectual property.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 6.52%
Debt Cost 6.31%
Equity Weight 93.48%
Equity Cost 6.31%
WACC 6.31%
Leverage 6.97%

11. Quality Control: Kezar Life Sciences, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
OncoCyte

A-Score: 4.7/10

Value: 7.1

Growth: 5.9

Quality: 3.1

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Kezar Life Sciences

A-Score: 3.7/10

Value: 8.0

Growth: 5.6

Quality: 4.2

Yield: 0.0

Momentum: 3.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Biomea Fusion

A-Score: 3.3/10

Value: 6.9

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Allogene Therapeutics

A-Score: 3.0/10

Value: 7.6

Growth: 4.3

Quality: 4.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Pliant Therapeutics

A-Score: 2.6/10

Value: 8.0

Growth: 3.1

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Maravai LifeSciences

A-Score: 2.5/10

Value: 7.1

Growth: 2.1

Quality: 3.9

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.37$

Current Price

7.37$

Potential

-0.00%

Expected Cash-Flows